Literature DB >> 2097382

Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules.

R C Armstrong1, L Harvath, M E Dubois-Dalcq.   

Abstract

During central nervous system (CNS) development, glial precursors proliferate in subventricular zones and then migrate throughout the CNS to adopt their final destinations and differentiate into various types of mature glial cells. Although several growth factors promoting the proliferation and/or differentiation of glial precursors have been identified, very little is known about the nature of signals that guide glial cell migration in the CNS. Therefore, we have investigated whether polypeptide growth factors and/or extracellular matrix molecules may mediate the migration of two major glial cell types, type 1 astrocytes and oligodendrocyte-type 2 astrocyte (O-2A) progenitor cells. We show that, in a microchemotaxis chamber assay, type 1 astrocytes move toward laminin and complement-derived C5a. Astrocyte migration toward laminin is inhibited by a laminin-specific pentapeptide, YIGSR-NH2. In contrast, O-2A progenitors migrate toward platelet-derived growth factor (PDGF), which also functions as a mitogen for these cells. Using a new method to simultaneously assay migration and DNA synthesis, we also demonstrate that O-2A progenitors can migrate toward PDGF even when DNA replication is inhibited with an antimitotic agent. Thus, migration of different types of glial cells can be induced in vitro by specific signaling molecules, which are present in the developing brain and may stimulate migration of glial cells prior to CNS myelination.

Mesh:

Substances:

Year:  1990        PMID: 2097382     DOI: 10.1002/jnr.490270319

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  55 in total

1.  Cell-surface glycoprotein of oligodendrocyte progenitors involved in migration.

Authors:  A Niehaus; J Stegmüller; M Diers-Fenger; J Trotter
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of alpha(v)beta3 integrins.

Authors:  Wia Baron; Sanford J Shattil; Charles ffrench-Constant
Journal:  EMBO J       Date:  2002-04-15       Impact factor: 11.598

Review 3.  Myelin biogenesis: vesicle transport in oligodendrocytes.

Authors:  J N Larocca; A G Rodriguez-Gabin
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 4.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

Review 5.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

6.  Glial progenitor cell recruitment drives aggressive glioma growth: mathematical and experimental modelling.

Authors:  Susan Christine Massey; Marcela C Assanah; Kim A Lopez; Peter Canoll; Kristin R Swanson
Journal:  J R Soc Interface       Date:  2012-02-07       Impact factor: 4.118

Review 7.  From stem cells to oligodendrocytes: prospects for brain therapy.

Authors:  Cui P Chen; Mary E Kiel; Dorota Sadowski; Randall D McKinnon
Journal:  Stem Cell Rev       Date:  2007-12       Impact factor: 5.739

8.  K+ channel expression and cell proliferation are regulated by intracellular sodium and membrane depolarization in oligodendrocyte progenitor cells.

Authors:  P Knutson; C A Ghiani; J M Zhou; V Gallo; C J McBain
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

9.  Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus.

Authors:  T N Behar; A E Schaffner; C A Scott; C O'Connell; J L Barker
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

Review 10.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.